KRAS and colorectal carcinoma: In a randomized phase Ib/II trial was tested AMG 102 (Rilotumumab, Amgen, Thousand Oaks, CA, USA), a humanized monoclonal antibody directed against HGF [60], in combination with panitumumab versus panitumumab plus placebo in KRAS wild-type advanced CRC population [61].